Nathalia Caroline Santiago E Souza1, Alvina Clara Félix2, Anderson Vicente de Paula2, José Eduardo Levi2, Claudio Sérgio Pannuti2, Camila Malta Romano3. 1. Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 2. Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, Brazil. 3. Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Hospital das Clinicas HCFMUSP (LIM52), Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. Electronic address: cmromano@usp.br.
Abstract
OBJECTIVES: This study was performed to determine whether neutralizing antibodies against yellow fever virus (YFV) generated by YFV vaccine could interfere in the specificity of dengue virus (DENV) and Zika virus (ZIKV) IgG ELISA tests. METHODS: Seventy-nine pairs of serum samples (pre- and post-vaccination), collected during the years 1997-1998 from children with no history of yellow fever disease who had been vaccinated against YFV, were tested. The seroconversion post-vaccination was evaluated through plaque reduction neutralization test (PRNT), and four different commercial ELISA kits were used for the detection of DENV and ZIKV IgG antibodies. RESULTS: A cross-reactivity rate of 3.9% with DENV IgG antibodies was found only with the Dengue Virus IgG Dx Select kit (Focus Diagnostics). CONCLUSIONS: As several countries have local transmission of multiple arboviruses, the absence of cross-reactivity or minimum cross-reactivity of YFV neutralizing antibodies with DENV and ZIKV antigens is a relevant finding, since the interpretation of sero-epidemiological investigations would be seriously impacted in many regions where YFV vaccination is mandatory.
OBJECTIVES: This study was performed to determine whether neutralizing antibodies against yellow fever virus (YFV) generated by YFV vaccine could interfere in the specificity of dengue virus (DENV) and Zika virus (ZIKV) IgG ELISA tests. METHODS: Seventy-nine pairs of serum samples (pre- and post-vaccination), collected during the years 1997-1998 from children with no history of yellow fever disease who had been vaccinated against YFV, were tested. The seroconversion post-vaccination was evaluated through plaque reduction neutralization test (PRNT), and four different commercial ELISA kits were used for the detection of DENV and ZIKV IgG antibodies. RESULTS: A cross-reactivity rate of 3.9% with DENV IgG antibodies was found only with the Dengue Virus IgG Dx Select kit (Focus Diagnostics). CONCLUSIONS: As several countries have local transmission of multiple arboviruses, the absence of cross-reactivity or minimum cross-reactivity of YFV neutralizing antibodies with DENV and ZIKV antigens is a relevant finding, since the interpretation of sero-epidemiological investigations would be seriously impacted in many regions where YFV vaccination is mandatory.
Authors: Lawrence Henry Ofosu-Appiah; Dodzi Kofi Amelor; Bright Ayensu; Ernest Akyereko; Nafisah Issah Rabiwu; David Opare; Godfred Owusu-Okyere; Dennis Odai Laryea; Franklin Asiedu-Bekoe; Julius Abraham Addo Mingle Journal: PLoS One Date: 2022-01-07 Impact factor: 3.240
Authors: Patrick Reteng; Linh Nguyen Thuy; Tam Tran Thi Minh; Maria Angélica Monteiro de Mello Mares-Guia; Maria Celeste Torres; Ana Maria Bispo de Filippis; Yasuko Orba; Shintaro Kobayashi; Kyoko Hayashida; Hirofumi Sawa; William W Hall; Lan Anh Nguyen Thi; Junya Yamagishi Journal: Sci Rep Date: 2021-09-24 Impact factor: 4.379
Authors: Simon Pollett; Caitlin H Kuklis; David A Barvir; Richard G Jarman; Rachel M Romaine; Brett M Forshey; Gregory D Gromowski Journal: PLoS Negl Trop Dis Date: 2022-01-21